Back to Authors

Shill, Holly A.

https://orcid.org/0000-0003-1284-5038

Mayo Clinic

Barrow Neurological Institute

Citations 92

Risk of Developing Dementia in Essential Tremor (S53.004)
Shill, Holly A. , Hentz, Joe, Belden, Christine M. , Powell, Jessica, Jacobson, Sandra A. , Caviness, John N., Beach, Thomas G. , Adler, Charles, Sabbagh, Marwan Noel

Neurology | December 7, 2023 | Volume: 80 | Issue: 7_supplement | Pages: No page available

10.1212/wnl.80.7_supplement.s53.004 Get It

Neuropathological Correlates of Visual Hallucinations in Parkinsonism (S03.006)
Morshed, Trisha, Jacobson, Sandra A. , Beach, Thomas G. , Shill, Holly A. , Caviness, John N., Belden, Christine M. , Sue, Lucia I., Davis, Kathryn, Adler, Charles H. , Sabbagh, Marwan Noel , Hu, Chengcheng

Neurology | December 7, 2023 | Volume: 80 | Issue: 7_supplement | Pages: No page available

10.1212/wnl.80.7_supplement.s03.006 Get It

Olfactory dysfunction in incidental Lewy body disease and Parkinson's disease: An update (P4-11.005)
Hasan, Shemonti , Sue, Lucia I., Shill, Holly A. , Mehta, Shyamal H. , Beach, Thomas G. , Driver‐Dunckley, Erika , Adler, Charles H. , Zhang, Nan , Serrano, Geidy E.

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.3775 Get It

Accuracy of the Early Diagnosis of Parkinson's Disease
Beach, Thomas G. , Adler, Charles H. , Shill, Holly A. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Adler, C H , Zhang, Nan , Serrano, Geidy E.

Movement Disorders | August 11, 2023 | Volume: 38 | Issue: 8 | Pages: 1573-1574

10.1002/mds.29556 Get It

Longitudinal motor decline in dementia with Lewy bodies, Parkinson disease dementia, and Alzheimer's dementia in a community autopsy cohort
Choudhury, Parichita , Belden, Christine M. , Driver‐Dunckley, Erika, Mehta, Shyamal H. , Shill, Holly A. , Beach, Thomas G. , Driver-Dunckley, Erika, Choudhury, Parichita , Zhang, Nan , Adler, Charles H. , Chen, Kewei , Driver‐Dunckley, Erika , Shprecher, David , Serrano, Geidy E. , Atri, Alireza

Alzheimer's & Dementia | July 8, 2023 | Volume: 19 | Issue: 10 | Pages: 4377-4387

10.1002/alz.13357 Get It

Abstract INTRODUCTION We examined the progression of extrapyramidal symptoms and signs in autopsy‐confirmed dementia with Lewy bodies (DLB), Parkinson's disease dementia (PDD), and Alzheimer's disease dementia (AD). METHODS Longitudinal data were obtained from Arizona Study of Aging and Neurodegenerative Disease, with PDD ( n = 98), AD ( n = 47) and DLB ( n = 48) further sub‐grouped as with or without parkinsonism (DLB+ and DLB−). Within‐group Unified Parkinson's Disease Rating Scale (UPDRS) ‐II and UPDRS‐III trajectories were analyzed using non‐linear mixed effects models. RESULTS In DLB, 65.6% had parkinsonism. Baseline UPDRS‐II and III scores (off‐stage) were highest ( P < 0.001) for PDD (mean ± SD 14.3 ± 7.8 and 27.4 ± 16.3), followed by DLB+ (6.0 ± 8.8 and 17.2 ± 17.1), DLB− (1.1 ± 1.3 and 3.3 ± 5.5) and AD (3.2 ± 6.1 and 8.2 ± 13.6). Compared to PDD, the DLB+ group had faster UPDRS‐III progression over 8‐years (Cohen's‐ d range 0.98 to 2.79, P < 0.001), driven by gait ( P < 0.001) and limb bradykinesia ( P = 0.02) subscales. DISCUSSION Motor deficits progress faster in DLB+ than PDD, providing insights about expected changes in motor function. Highlights Dementia with Lewy bodies has faster motor progression than Parkinson's disease dementia Linear and non‐linear mixed modeling analysis of longitudinal data was utilized Findings have implications for clinical prognostication and trial design
Low Clinical Sensitivity and Unexpectedly High Incidence for Neuropathologically Diagnosed Progressive Supranuclear Palsy (PSP) (S51.001)
Driver‐Dunckley, Erika , Dunckley, Nathaniel, Sue, Lucia I., Shill, Holly A. , Mehta, Shyamal H. , Belden, Christine M. , Beach, Thomas G. , Zhang, Nan , Serrano, Geidy E. , Tremblay, Cécilia , Atri, Alireza , Adler, Charles H.

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000202619 Get It

Cerebral white matter rarefaction has both neurodegenerative and vascular causes and may primarily be a distal axonopathy
Beach, Thomas G. , Sue, Lucia I., Scott, Sarah, Intorcia, Anthony J., Walker, Jessica E. , Arce, Richard, Glass, Michael J. , Borja, Claryssa I., Cline, Madison P. , Hemmingsen, Spencer J, Qiji, Sanaria H., Stewart, Analisa M. , Martinez, Kayleigh N, Krupp, Addison, McHattie, Rylee, Mariner, Monica, Lorenzini, Ileana , Kuramoto, Angela, Long, Kathy E., Tremblay, Cécilia , Caselli, Richard J. , Woodruff, Bryan K. , Rapscak, Steven Z., Belden, Christine M. , Goldfarb, Danielle, Driver‐Dunckley, Erika , Mehta, Shyamal H. , Shill, Holly A. , Driver-Dunckley, Erika D., Adler, C H , Choudhury, Parichita , Sabbagh, Marwan Noel , Atri, Alireza , Adler, Charles H. , Serrano, Geidy E.

Journal of Neuropathology & Experimental Neurology | April 18, 2023 | Volume: 82 | Issue: 6 | Pages: 457-466

10.1093/jnen/nlad026 Get It

Abstract Cerebral white matter rarefaction (CWMR) was considered by Binswanger and Alzheimer to be due to cerebral arteriolosclerosis. Renewed attention came with CT and MR brain imaging, and neuropathological studies finding a high rate of CWMR in Alzheimer disease (AD). The relative contributions of cerebrovascular disease and AD to CWMR are still uncertain. In 1181 autopsies by the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND), large-format brain sections were used to grade CWMR and determine its vascular and neurodegenerative correlates. Almost all neurodegenerative diseases had more severe CWMR than the normal control group. Multivariable logistic regression models indicated that Braak neurofibrillary stage was the strongest predictor of CWMR, with additional independently significant predictors including age, cortical and diencephalic lacunar and microinfarcts, body mass index, and female sex. It appears that while AD and cerebrovascular pathology may be additive in causing CWMR, both may be solely capable of this. The typical periventricular pattern suggests that CWMR is primarily a distal axonopathy caused by dysfunction of the cell bodies of long-association corticocortical projection neurons. A consequence of these findings is that CWMR should not be viewed simply as “small vessel disease” or as a pathognomonic indicator of vascular cognitive impairment or vascular dementia.
Low clinical sensitivity and unexpectedly high incidence for neuropathologically diagnosed progressive supranuclear palsy
Driver‐Dunckley, Erika , Dunckley, Nathaniel, Sue, Lucia I., Shill, Holly A. , Mehta, Shyamal H. , Belden, Christine M. , Tremblay, Cécilia , Beach, Thomas G. , Driver-Dunckley, Erika D., Zhang, Nan , Serrano, Geidy E. , Atri, Alireza , Adler, Charles H.

Journal of Neuropathology & Experimental Neurology | April 11, 2023 | Volume: 82 | Issue: 5 | Pages: 438-451

10.1093/jnen/nlad025 Get It

Abstract The objective of this study was to determine the prevalence, incidence, and clinical diagnostic accuracy for neuropathologically diagnosed progressive supranuclear palsy (PSP) with data from a longitudinal clinicopathological study using Rainwater criteria to define neuropathological PSP. Of 954 autopsy cases, 101 met Rainwater criteria for the neuropathologic diagnosis of PSP. Of these, 87 were termed clinicopathological PSP as they also had either dementia or parkinsonism or both. The prevalence of clinicopathologically defined PSP subjects in the entire autopsy dataset was 9.1%, while the incidence rate was estimated at 780 per 100 000 persons per year, roughly 50-fold greater than most previous clinically determined PSP incidence estimates. A clinical diagnosis of PSP was 99.6% specific but only 9.2% sensitive based on first examination, and 99.3% specific and 20.7% sensitive based on the final clinical exam. Of the clinicopathologically defined PSP cases, 35/87 (∼40%) had no form of parkinsonism at first assessment, while this decreased to 18/83 (21.7%) at final assessment. Our study confirms a high specificity but low sensitivity for the clinical diagnosis of PSP. The low clinical sensitivity for PSP is likely primarily responsible for previous underestimates of the PSP population incidence rate.
Lack of significant Lewy pathology in 237 essential tremor brains
Shill, Holly A. , Tremblay, Cécilia , Beach, Thomas G. , Adler, Charles H.

Journal of Neuropathology & Experimental Neurology | March 21, 2023 | Volume: 82 | Issue: 5 | Pages: 452-453

10.1093/jnen/nlad022 Get It

Postmortem Cerebellar Volume Is Not Reduced in Essential Tremor: A Comparison with Multiple System Atrophy and Controls
Tremblay, Cécilia , Dunckley, Nathaniel, Zhang, Nan , Fiock, Kimberly L. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Shill, Holly A. , Beach, Thomas G. , Driver-Dunckley, Erika, Serrano, Geidy E. , Adler, Charles H.

Journal of Parkinson’s Disease | March 14, 2023 | Volume: 13 | Issue: 3 | Pages: 333-340

10.3233/jpd-225033 Get It

Background: Essential tremor (ET) is a common movement disorder in which cerebellar microscopic and volume alterations have been repeatedly reported although with disagreement between studies. However, pronounced heterogeneity was found with regard to cerebellar volume alterations. Objective: This study aimed to assess postmortem cerebellar volume in subjects with or without ET, as compared with subjects with multiple system atrophy (MSA), a well-established cerebellar neurodegeneration. Methods: Cases with ET ( n = 29), MSA ( n = 7), and non-demented control cases without any movement disorder ( n = 22) were selected from the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND), a longitudinal clinicopathological study with annual research-dedicated clinical assessments by neuropsychologists, subspecialist movement disorders, and cognitive/behavioral neurologists, with comprehensive neuropathological examinations after death. Group comparisons were controlled for common age-related neurodegenerative and cerebrovascular pathologies. Cerebellar volumes were calculated using digital images of slices taken at the time of autopsy, immediately after brain removal and before fixation. Results: Cerebellar volume was not reduced in ET subjects compared to controls. The two groups did not differ in terms of incidental cerebrovascular and Alzheimer’s disease neuropathology. In contrast, cerebellar volume was significantly reduced in subjects with MSA when compared to ET and control subjects. Conclusion: In a well-characterized cohort, postmortem cerebellar volume measurements suggest that there are no volume alterations in ET when compared to controls, in contrast to significant cerebellar atrophy in subjects with MSA.